Characterization of Alisertib (MLN8237), An Investigational Small Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

Running title: In vitro and in vivo characterization of alisertib
[maximum 50 characters; currently 50]

Authors: 1

Author affiliations:
1Millennium Pharmaceuticals Inc., Cambridge, MA, USA

Corresponding author:
Mark G. Manfredi
Address: 40 Landsdowne Street Cambridge MA 02139
Phone: 617-679-7382
Fax: 617-551-8906
E-mail: mark.manfredi@mpi.com

Address for reprint requests: As above.

Financial disclosure/conflicts of interest: All authors are employees of Millennium Pharmaceuticals Inc., thus this work was supported in full by Millennium Pharmaceuticals Inc.

Journal section designation: Research Articles – Preclinical Therapy
Deputy Editor or Senior Editor selected to conduct review process:
Josep Tabernero

Colorectal neoplasms, GI neoplasms, EGFR, mTor, PI3K, clinical trials, Phase I clinical trials

Suggested reviewers:
Robert Wilkinson - AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom.
Email: robert.wilkinson@astrazeneca.com

Michael Henry, Ph.D. - Office: 6-510 Bowen Science Building
Lab: 6-509 Bowen Science Building
Phone: (319) 335-7886
Lab: (319) 335-7887
FAX: (319) 335-7330
Email: michael-henry@uiowa.edu

Key words: (max 5) Alisertib, Aurora A kinase, Mitosis, Pharmacodynamic

Manuscript details
Target journal: Clinical Cancer Research
Abstract word count: 248 words [Max 250]
Article word count: 4476 words [Max 5,000]
Figures/tables: 4/2 [Max 6] + 4 supplementary figures
References: 47 [Max 50]

Co-author contact details:

<table>
<thead>
<tr>
<th>First name</th>
<th>Last name</th>
<th>Postal address</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey</td>
<td>Ecsedy</td>
<td>40 Landsdowne Street</td>
<td><a href="mailto:Jeffrey.Ecsedy@mpi.com">Jeffrey.Ecsedy@mpi.com</a></td>
</tr>
<tr>
<td>Arijit</td>
<td>Chakravarty</td>
<td>Cambridge MA 02139</td>
<td><a href="mailto:Arijit.Chakravarty@mpi.com">Arijit.Chakravarty@mpi.com</a></td>
</tr>
<tr>
<td>Lee</td>
<td>Silverman</td>
<td></td>
<td><a href="mailto:Lee.Silverman@mpi.com">Lee.Silverman@mpi.com</a></td>
</tr>
<tr>
<td>Mengkun Zhang</td>
<td><a href="mailto:Mengkun.Zhang@mpi.com">Mengkun.Zhang@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kara M. Hoar</td>
<td><a href="mailto:Kara.Hoar@mpi.com">Kara.Hoar@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen G. Stroud</td>
<td><a href="mailto:Stephen.Stroud@mpi.com">Stephen.Stroud@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wei Chen</td>
<td><a href="mailto:Wei.Chen@mpi.com">Wei.Chen@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaishali Shindi</td>
<td><a href="mailto:Vaishali.Shindi@mpi.com">Vaishali.Shindi@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jessica Huck</td>
<td><a href="mailto:Jessica.Huck@mpi.com">Jessica.Huck@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deborah Wysong</td>
<td><a href="mailto:Deborah.Wysong@mpi.com">Deborah.Wysong@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Janowick</td>
<td><a href="mailto:David.Janowick@mpi.com">David.Janowick@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marc Hyer</td>
<td><a href="mailto:Marc.Hyer@mpi.com">Marc.Hyer@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patrick LeRoy</td>
<td><a href="mailto:Patrick.LeRoy@mpi.com">Patrick.LeRoy@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rachel Gershman</td>
<td><a href="mailto:Rachel.Gershman@mpi.com">Rachel.Gershman@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthew Silva</td>
<td><a href="mailto:Matthew.Silva@mpi.com">Matthew.Silva@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melissa Germanos</td>
<td><a href="mailto:Melissa.Germanos@mpi.com">Melissa.Germanos@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joseph Bolen</td>
<td><a href="mailto:Joseph.Bolen@mpi.com">Joseph.Bolen@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christopher Claiborne</td>
<td><a href="mailto:Christopher.Claiborne@mpi.com">Christopher.Claiborne@mpi.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Todd Sells</td>
<td><a href="mailto:Todd.Sells@mpi.com">Todd.Sells@mpi.com</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Statement of Translational Relevance: (max 150 words; currently 143)

Aurora A Kinase (AAK) has been implicated in oncogenesis and tumor progression, and is amplified or overexpressed in several tumor types. In this article we describe the development of three novel biomarker assays of AAK activity that provide detailed and specific information regarding the biological effects of AAK inhibition \textit{in vivo}. The novel assays therefore provide a basis for translating the mechanism of action of AAK inhibitors into clinically informative pharmacodynamic endpoints. In conjunction with established methods, these assays were used to describe the \textit{in vitro} and \textit{in vivo} antitumor activity of an investigational AAK inhibitor, alisertib (MLN8237). Our data indicate that alisertib is a selective and potent inhibitor of AAK, and supports its continued clinical development as an anticancer agent. Furthermore, the assays described here are currently being deployed in phase I studies to help characterize the activity of alisertib in patients.
Abstract (max 250 words; currently 250)

Purpose: Small-molecule inhibitors of Aurora A (AAK) and B (ABK) kinases, which play important roles in mitosis, are currently being pursued in oncology clinical trials. We developed three novel assays to quantitatively measure biomarkers of AAK inhibition in vivo. Here we describe preclinical characterization of alisertib (MLN8237), a selective AAK inhibitor, incorporating these novel pharmacodynamic assays.

Experimental Design: We investigated the selectivity of alisertib for AAK and ABK, and studied the antitumor and antiproliferative activity of alisertib in vitro and in vivo. Novel assays were used to assess chromosome alignment and mitotic-spindle bipolarity in human tumor xenografts using immunofluorescent detection of DNA and alpha-tubulin, respectively. In addition, 18F-3′-fluoro-3′-deoxy-L-thymidine positron emission tomography (FLT-PET) was used to non-invasively measure effects of alisertib on in-vivo tumor cell proliferation.

Results: Alisertib inhibited AAK over ABK with a selectivity >200-fold in cells, and produced a dose-dependent decrease in bipolar and aligned chromosomes in the HCT-116 xenograft model, a phenotype consistent with AAK inhibition. Alisertib inhibited proliferation of human tumor cell lines in vitro, and produced tumor growth inhibition in solid-tumor xenograft models, and regressions in in-vivo lymphoma models. In addition, a dose of alisertib that caused tumor stasis as measured by volume, resulted in a decrease in FLT-uptake suggesting that non-invasive imaging could provide value over traditional measurements of response.
Conclusions: Alisertib is a selective and potent inhibitor of AAK. The novel methods of measuring Aurora A pathway inhibition and application of tumor imaging described here may be valuable for clinical evaluation of small-molecule inhibitors.
Introduction

Mitotic kinases, kinesins and other mitotic enzymes are being pursued as targets for the next generation of antimitotic therapies in oncology. While several molecules have demonstrated clinical efficacy, it is too early to know if they will add benefit beyond classic microtubule antagonists such as the taxanes and vinca alkaloids. So far however, it is clear that the newer agents are unlikely to cause the peripheral neuropathy often observed in patients treated with microtubule-targeting drugs (1).

The conventional view of antimitotic agents is that they cause prolonged mitotic arrest leading to cell death. In recent years, this perspective has been modified to incorporate two alternative outcomes following mitotic delays in metaphase (2, 3). Studies using live-cell microscopy with a variety of antimitotic agents in a range of cell lines have reported a striking diversity of responses (4-6). In some sensitive cell lines, mitotic arrest is sustained until cells die directly from prometaphase. In other sensitive cell lines, the mitotic delay is transient, and is followed by an inappropriate segregation of unaligned chromosomes (4, 5, 7). This mitotic slippage is followed by a variety of terminal outcomes that appear to include post-mitotic death as well as terminal growth arrest (cellular senescence) (8, 9). Evidence exists to support the view that cytostasis (10, 11), as well as post-mitotic cell death (5) are significant drivers of the antiproliferative effects of taxanes.
The complex mechanism of action of antimitotic agents has posed a significant challenge for the development of pharmacodynamic biomarkers for their action. The obvious and traditional biomarker, the mitotic index, is hampered by the cell-line-to-cell-line differences in the duration of mitotic arrest (4, 5), and by the tendency of low concentrations of antimitotic agents to reduce cellular viability without a prolonged mitotic arrest, via a mitotic slippage-based mechanism (12, 13). Surprisingly, even within the same cell type, there is often a diversity of responses to the same mitotic inhibitor at different concentrations (4, 5, 13), and heterogeneity in the degree of mitotic arrest versus mitotic slippage within the same population of cells (4, 5). Consistent with these findings, the length of mitotic arrest within a given cell type has been found not to correlate with probability of death (4, 5).

This weak linkage between mitotic arrest and cell death provides us with a retrospective explanation for the failure of early attempts to use the mitotic index to provide guidance for taxane development. For these agents, preclinical in vivo work showed minimal (14) or nonexistent (15) predictive value for mitotic index with respect to anticipating the degree of tumor growth inhibition, which was later corroborated in patient tumor biopsies (16).

Aurora A and Aurora B are related serine/threonine kinases that share significant sequence similarity but differ in their localization, substrate specificity, and function. The function of these kinases has been reviewed extensively (17-
among other functions, Aurora A is essential for normal mitotic spindle formation and centrosome maturation and separation (20). Several Aurora kinase inhibitors are currently undergoing clinical development. These include molecules that are Aurora A selective, Aurora B selective, dual Aurora A and Aurora B inhibitors, and multikinase inhibitors which include activity against the Aurora kinases (21, 22). Early results from clinical trials of alisertib (MLN8237) and other Aurora kinase inhibitors have shown promising antitumor activity and prolonged stable disease (23-27).

Although inhibition of Aurora kinases can alter the microtubule network,(7) a potentially unique feature that may distinguish Aurora kinase inhibitors from the microtubule antagonists as anticancer agents is the additional regulatory functions the Aurora kinases play. For example, Aurora A directly binds to and regulates the turnover of N-myc, and may be essential in N-myc amplified neuroblastomas (28). In addition, both Aurora A and Aurora B have been shown to phosphorylate and regulate p53 function in experimental systems (29, 30). Determining which of these additional functions are most important for tumor survival should provide insights into patient stratification strategies or rational combination approaches.

Inhibition of Aurora A kinase leads to the formation of mitotic spindle defects and misaligned chromosomes (7, 31, 32). However, despite these mitotic defects, cells lacking functional Aurora A often divide, albeit abnormally (7, 33).
This inappropriate division in the presence of spindle defects appears to be the result of compromised spindle assembly checkpoint function (34). The abnormal mitotic divisions result in deleterious aneuploidy and chromosomal instability leading to cell death or arrest (7). However, a portion of cells can recover from these outcomes and can reenter the cell cycle. The alternative fates subsequent to post-mitotic defects induced by Aurora A and Aurora B kinase inhibition are mediated in part by the p53 and p73 signaling pathways (35, 36). Additionally, Aurora A inhibition in a range of cell types has been demonstrated to lead to a reduction in the rate of mitotic entry due to a late G2 block in the cell cycle (37-40). As is the case for traditional antimitotic agents, this complexity in the downstream cell biological consequences of Aurora A inhibition has led to challenges in the use of the mitotic index as a pharmcodynamic measurement in tumors. In particular, we have previously shown that the mitotic index is an early marker of Aurora A inhibition (32), which decays gradually over time due to a loss of the cycling population of cells.

To address these limitations in the use of mitotic index in drug development, we developed three novel assays to quantitatively measure biomarkers of Aurora A inhibition in vivo. The first two assays, as reported initially in Chakravarty et al (41), assess chromosome alignment and spindle bipolarity, while the final utilizes 18F-3'-fluoro-3'-deoxy-L-thymidine positron emission tomography (FLT-PET) to non-invasively measure tumor cell proliferation. Taken together, the assessed biomarkers provide a more complete view of the
biological effects of Aurora A inhibition in vivo, and have provided a basis for translation of mechanism of action into clinically informative pharmacodynamic endpoints. In this paper, we detail these novel methods for quantifying Aurora A inhibition in vivo, and using these and other established methods, describe the in vitro and in vivo antitumor activity of alisertib against Aurora A kinase. The phenotypic biomarkers are now being used to analyze tumor biopsies in clinical studies (41), while the functional imaging approaches have been used to monitor alisertib activity.

Material and Methods

**Enzyme and cell-based assays to measure kinase inhibition.** Aurora A and Aurora B radioactive Flashplate® enzyme assays and cell-based assays were conducted to determine the nature and degree of alisertib-mediated inhibition in vitro, as described by Manfredi et al (32). In the cell-based assays, Aurora A activity was determined by measuring autophosphorylation of Aurora A on threonine 288, while Aurora B activity was determined by measuring phosphorylation of histone H3 on Serine 10 (pHisH3), in both cases using high content imaging assays, and as previously described (32). The inhibitory activity of 1 µM alisertib was also tested against 205 kinases (SelectScreen™ kinase panel, Invitrogen, Carlsbad, CA).

**Flow cytometry.** HCT-116 colorectal carcinoma cells (American Type Culture Collection [ATCC], Manassas, Virginia) were plated on 6-well dishes (2 ×
10^5/well) and propagated in McCoy’s 5A media (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS). After 18 hrs, alisertib at a final concentration of 0.050, 0.250, or 1.000µM was added, and the cells were grown for an additional 24 hrs. Cells treated with dimethyl sulfoxide (DMSO; 0.2%) served as the untreated vehicle control. The cells were harvested with trypsin ethylenediamine-tetraacetic acid (EDTA) 1X (Gibco), washed once with phosphate-buffered saline (PBS), fixed in 70% ethanol and stored at 4°C for 1 hr. The cells were re-suspended in propidium iodide (1:40, Molecular Probes, Carlsbad, CA) and ribonucleic acidase (RNAse) A (1:5000, Sigma, St. Louis, MO) in PBS for 30 mins at 4°C. Cell cycle distributions were determined by measuring deoxyribonucleic acid (DNA) content using flow cytometry (FACS Calibur; Becton Dickenson, Franklin Lakes, NJ) and samples were analyzed using Winlist 5.0 software (Verity Topsham, ME).

**Immunofluorescent staining.** HCT-116 cells were grown for 24 hrs on glass coverslips in McCoy’s 5A media supplemented with 10% FBS, and alisertib diluted in DMSO to 0.050, 0.250, and 1.000 µM. Cells treated with DMSO served as the vehicle control. Immunofluorescence staining was performed with anti-α-tubulin mouse antibodies (diluted 1:1000; Sigma) and Hoescht (diluted 1:50,000; Molecular Probes). Images were captured as previously described (32).

**BrdU in vitro cell proliferation assay.** Thirteen tumor cell lines treated with increasing concentrations of alisertib over 96 hrs were subjected to 5-bromo-
2-deoxyuridine (BrdU) incorporation as a measurement of cellular proliferation. Proliferation of each cell line was measured using the cell proliferation enzyme-linked immunosorbent assay (ELISA), BrdU colorimetric kit according to the manufacturer’s recommendations (Roche, Basel Switzerland), and as previously described (32).

**In vivo efficacy studies.** Nine *in vivo* tumor models of different histologies grown subcutaneously or disseminated were developed in either nude or SCID mice (Charles River, Wilmington MA). The methods for all *in vivo* studies have been described previously (32), with the exception of the lymphoma tumor models described below. All mice had access to food and water ad libitum, and were housed and handled in accordance with the Guide for the Care and Use of Laboratory Animals, and Millennium Institutional Animal Care and Use Committee Guidelines. Mice for all models were dosed orally with alisertib for approximately three weeks and tumor growth inhibition (TGI) was calculated on the last day of treatment. For all studies, alisertib was formulated in 10% 2-hydroxypropyl-β-cyclodextrin and 1% sodium bicarbonate, and was dosed orally by gavage on a once-daily (QD) or twice-daily (BID) schedule.

The cell lines OCI-LY7-Luc, OCI-LY19-Luc and WSU-DLCL2-Luc were used for lymphoma models; tumor cells were inoculated intravenously into 5–8 week old female SCID (NOD-SCID (Taconic, Hudson NY) in study of OCI-LY7-Luc) mice. Mice bearing the disseminated, CD20-positive, non-Hodgkin’s
lymphoma model OCI-LY19 were treated with vehicle control (10% 2-hydroxypropyl-β-cyclodextrin and 1% sodium bicarbonate was used for all in vivo studies), alisertib at 20 mg/kg BID or 30 mg/kg QD, or the anti-CD20 monoclonal antibody rituximab (Rituxan®, Genentech, South San Francisco, CA) at 10 mg/kg once per week. The lymphoma cell lines stably expressed firefly luciferase, and tumor growth over time was measured using whole body bioluminescent imaging using Xenogen IVIS 200 imaging system (Caliper, Hopkinton, MA). Fifteen mins prior to imaging, mice received an intraperitoneal injection of 150 mg/kg of the substrate luciferin (Caliper, Hopkinton, MA) which when oxidized by luciferase, emits light photons. Mice were imaged both dorsally and ventrally, and photon flux values where summed from both views. The antitumor effects of each treatment group were determined by calculating the percent TGI ([Δ control mean tumor photon flux – Δ treated mean tumor photon flux] × 100/ Δ control mean tumor photon flux) at the end of treatment.

**Mitotic index, spindle bipolarity, and chromosome alignment assays.**

Mice bearing HCT-116 xenografts were treated orally with a single dose of 3, 10, and 30 mg/kg alisertib, and tumor samples were removed at specified time points. Frozen tumor tissue sections were stained for the mitotic marker pHisH3 then visualized using immunofluorescence detection, and quantified at the indicated time-points. The methods used to stain and quantify pHisH3, which is also an Aurora B substrate, have been described previously (32). Aurora B inhibition would result in a decrease in pHisH3, while Aurora A inhibition would result in an
increase in the mitotic marker (32). For chromosome alignment and spindle bipolarity assays, tumor samples were harvested from mice bearing HCT-116 xenograft tumors at specified time points, then formalin fixed and paraffin embedded. The samples were sectioned at 5 μm and stained using the Discovery® XT automated slide staining instrument (Ventana Molecular Discovery Systems, Tucson, AZ). Sections were deparaffinized on the instrument with EZ prep™ solution (Ventana Medical Systems, Tucson, AZ) and antigen retrieval was completed with CC1 (Ventana Medical Systems, Tucson, AZ). Immuno-fluorescence staining for tubulin was performed using a mouse anti-α tubulin clone DM1A fluorescein isothiocyanate (FITC)-conjugated antibody (1:100; Sigma, Saint Louis, Missouri), and for DNA using DAPI (Vector Laboratories, Burlingame CA) for 60 mins. For each mitotic cell, 26 focal planes spaced 0.2 μm apart were acquired using an automated Nikon microscope using 40X objective. To remove out-of-focus light the image stacks were processed using MetaMorph® imaging software (Molecular Devices, Sunnyvale, CA). Three dimensional projections of each cell were also generated using Metamorph® imaging software. These projections enable reconstruction of the entire spindle structure across the 5μm section thickness. The projections were presented in a randomized and blinded fashion to three scorers. Each mitotic cell was scored for chromosome alignment (aligned versus not aligned) and spindle bipolarity (bipolar versus not bipolar) according to pre-established criteria. Scorers have the option for a ‘no-call’ vote. Scores chosen by the majority of the reviewers
was used for subsequent calculations. Spindles and chromosomes for which no majority call existed were discounted from the analysis.

**FLT-PET.** HCT-116 cells (5 x 10^6 cells) diluted in 100uL PBS were inoculated subcutaneously into the right flank of 20 nude mice. When the tumors reached approximately 200 mm^3 by caliper measurement, the animals were randomized into vehicle and treatment groups (n = 8 per group), and received alisertib at 20 mg/kg BID or vehicle control, respectively, for a period of 21 days. PET imaging was conducted using the proliferation marker FLT, which reflects the activity of thymidine kinase 1 (42). FLT-PET scanning was conducted on days 0 (baseline), 7, 14, and 21 post alisertib treatment. Approximately 200 µCi (194-236 µCi, 7.2-8.7 MBq) of F^{18}-FLT (PETNET, Woburn, MA) was injected via tail vein on days 0 (before alisertib treatment), 7, 14, and 21, and allowed to distribute in conscious animals for 60 mins. Mice were then anesthetized with 2% isoflurane and positioned prone in a custom, two-animal holder. A 10-min scan was performed using the R4 microPET system (Siemens Medical, Knoxville, TN), followed by a 10-min attenuation correction scan. Tomographic images were subsequently reconstructed using the 2D ordered subset expectation maximization method. To minimize the influence of necrotic tissue in the HCT-116 xenograft during image analysis, a 27 mm^3 volume-of-interest (VOI) within a viable region of the tumor was selected using AMIDE software (Molecular Imaging Program at Stanford, Stanford University) (43). The data was
analyzed as the standardized uptake value (SUV) of the VOI, SUV_{VOI}, and was normalized to baseline.

**Results**

*In vitro studies show that alisertib inhibits Aurora A kinase and is selective over family member Aurora B kinase and other kinases.* Alisertib has a benzazepine core structure with a fused amino pyrimidine ring and an aryl carboxylic acid (Supplementary Fig. 1). In enzymatic assays, alisertib was a potent inhibitor of Aurora A kinase, with an IC_{50} value of 1.2 nM (Table 1). Alisertib has less activity against Aurora B kinase with an IC_{50} value of 396.5 nM in enzymatic assay. The cell-based assays demonstrated that alisertib was at least 200-fold more selective for Aurora A (IC_{50} = 6.7 nM) than Aurora B (IC_{50} = 1534 nM) (Supplementary Fig. 2). In addition, alisertib demonstrated selectivity in enzymatic assays against a 205-kinase panel (Supplementary Fig. 3).

Phenotypic cell-based assays supported the selectivity of alisertib for Aurora A kinase over Aurora B kinase. At a concentration of 0.050 µM alisertib, cell-cycle analysis using flow cytometry demonstrated an increase in cells in the G2/M phase at 24 and 48 hrs (Fig. 1A), a phenotype consistent with Aurora A inhibition (7, 32). In addition, cells treated at this concentration displayed mitotic spindle abnormalities and chromosome misalignment (Fig. 1B), phenotypes that were previously described to be associated with Aurora A inhibition (7). At higher concentrations of 0.250 and 1.000 µM, alisertib-treated cells demonstrated
phenotypes consistent with Aurora B inhibition. At these concentrations cell-cycle analysis showed an increase in the number of cells with 8N DNA content (Fig. 1A). In addition, immunofluorescent staining of chromosomes and α-tubulin suggested that these cells are multinucleated (Fig. 1B).

**Alisertib inhibits proliferation of tumor cells grown in culture from diverse origin.** Alisertib displayed antiproliferative activity in a broad panel of adherent and suspended cell lines (Table 1). Alisertib inhibited cell proliferation with IC₅₀ values ranging from 15 nM to 469 nM. In general, lymphoma cell lines were more sensitive to alisertib than solid tumor cell lines.

**Pharmacodynamic activity of alisertib in vivo: increased mitotic index, reduced bipolar mitotic spindles and increased chromosome alignment abnormalities.** Alisertib dosed orally at 3, 10, and 30 mg/kg in female nude mice bearing HCT-116 colon tumor xenografts resulted in significant bioavailability as measured by plasma and tumor concentrations (Supplementary Fig. 4). A dose of 30 mg/kg on a QD schedule was the maximum tolerated dose.

Analysis of tumor tissue from HCT-116 xenografts treated with increasing doses of alisertib revealed a time-dependent and dose-dependent increase in the mitotic marker pHisH3, suggesting that alisertib inhibited Aurora A (Fig. 2A). The plasma concentration at the time the mitotic marker was declining was approximately 1–2 μM, suggesting that this concentration is needed to inhibit
Aurora A kinase *in vivo* (Supplementary Fig. 4). Moreover, there was no inhibition of pHisH3 at concentrations of approximately 6 μM demonstrating a significant selectivity for Aurora A inhibition over Aurora B *in vivo*.

To further characterize the *in vivo* phenotype of Aurora A inhibition, tumors treated with alisertib at the doses used above were assessed for chromosome alignment and mitotic spindle defects. In order to assess mitotic tumor cells for chromosome alignment and spindle bipolarity, sections were stained for α-tubulin and DNA. Representative examples of mitotic cells from each of the time points in the first 4 hrs at all three dose levels are shown in Fig. 2B and illustrate a broad dose- and time-dependent decrease in the degree of chromosome alignment and spindle bipolarity during mitosis, consistent with the described mechanism of Aurora A. As the figure shows, mitotic spindles in the control sample demonstrated a high degree of chromosome alignment and bipolarity. Fig. 2C and D show that there was a relatively rapid dose-dependent decrease in chromosome alignment and spindle bipolarity, which appeared to peak around 1 hr after dosing at the 30 mg/kg dose. At this dose, there was a sharp reduction in both chromosome alignment and bipolarity throughout the first 4 hrs (Fig. 2C and D). At 4 hrs post-dose, many of the spindles demonstrated a monopolar phenotype, which is the most commonly reported effect of Aurora A inhibition. By 8 hrs, there was a partial recovery of spindle bipolarity in this dose group, but not chromosomal alignment, and the majority of spindles in this dose group were bipolar, with misaligned chromosomes. In the 10 mg/kg dose group, there was a
strong reduction in chromosome alignment and spindle bipolarity in the first 4 hrs (Fig 2C and D), followed by partial recovery of chromosome alignment and spindle bipolarity by 8 hrs. The effects observed in the 3 mg/kg dose group were more modest, with a partial reduction of chromosomal alignment and bipolarity at 4 hrs, followed by substantial recovery in chromosomal alignment by 8 hrs. Taken together, alisertib at all three doses exhibited phenotypes that were consistent with Aurora A inhibition.

**Alisertib causes tumor growth inhibition in solid tumor xenograft models and regressions in in vivo models of lymphoma.** To determine the in vivo antitumor activity of alisertib, mice bearing solid and hematological human tumor xenografts were administered increasing doses of alisertib. Fig. 3A shows average tumor volumes in nude mice bearing subcutaneous HCT-116 tumors after 3 weeks of oral alisertib at 3, 10, or 30 mg/kg QD. Alisertib treatment resulted in a dose-dependent TGI of 43.3%, 84.2%, and 94.7% for the 3, 10, and 30 mg/kg groups, respectively. The greatest antitumor response in this model was tumor stasis. All doses were well tolerated with the maximum body weight loss of 7.4% in the 30 mg/kg group.

As shown in Fig. 3B, alisertib treatment in the non-Hodgkin’s lymphoma model OCI-LY19 also resulted in tumor regression. Rituximab was used a control for this model, and resulted in moderate antitumor activity when dosed at 10 mg/kg once per week. Alisertib dosed at either 20 mg/kg BID or 30 mg/kg QD
resulted in a reduction in luminescent signal below baseline and a TGI of 106% for both groups. Moreover, tumors in the 20 mg/kg dose group did not grow back after more than 60 days of monitoring. Finally, alisertib demonstrated broad antitumor activity across a diverse set of xenograft models, with TGI of greater than 76% at 30 mg/kg in all models tested (Table 2).

**Alisertib reduces FLT uptake in HCT-116 xenograft tumors.** We have demonstrated that a dose of 20 mg/kg BID alisertib causes tumor stasis in the HCT-116 model, as measured volumetrically. We hypothesized that treated tumors with no change in tumor volume had a decrease in proliferating cells. Therefore, we monitored tumor response to alisertib using volumetric measurements or FLT uptake (as measured by SUV\textsubscript{Vol}) using PET imaging, to determine if non-invasive imaging of cell proliferation (as measured by FLT uptake) could be used to monitor alisertib activity, and test our hypothesis. Similar to the previous study, Fig. 4A shows that alisertib inhibits tumor volume growth when compared to vehicle controls, but does not result in tumor regressions. The difference between alisertib and vehicle groups was statistically different on days 14 and day 21 of treatment but not on day 7. While tumor volumes of alisertib-treated mice did not change over the course of treatment, FLT uptake, and therefore cell proliferation, significantly decreased, starting with the first measurement on day 7, as shown in Fig. 4B. By day 21, FLT uptake in the alisertib-treated tumors decreased by 51%, which was highly statistically significant ($P = 0.0014$ by two-tailed t-test, unequal variances). As expected, the
FLT uptake in tumors of the vehicle control animals did not change over the course of treatment. These results demonstrate that FLT-PET imaging may provide additional value for monitoring therapeutic response beyond volumetric measurements.

Discussion

Here we describe an orally active selective Aurora A small molecule inhibitor that is currently in clinical development. Alisertib demonstrated selectivity for Aurora A over Aurora B in enzyme and cell based assays, and in in vivo pharmacodynamic studies. At the maximal tolerated dose of 30 mg/kg on a daily dosing schedule, alisertib showed an increase in the mitotic index and remained pHisH3 immunopositive, a direct substrate of Aurora B. This demonstrates that while alisertib has the ability to inhibit Aurora B at higher concentrations in cells, it does not inhibit this kinase when dosed in vivo at the maximum tolerated dose (MTD). The selectivity of alisertib for Aurora A relative to Aurora B was also demonstrated in two human phase 1 clinical trials at the MTD when given QD or BID for 7 days, as alisertib treatment results in an increase in pHisH3 staining in both skin and tumor biopsies (44). These data demonstrate that at in vivo efficacious exposures alisertib is a functionally selective inhibitor of Aurora A kinase. In vitro immunofluorescent studies however, indicated that at higher alisertib concentrations, cells demonstrate phenotypes consistent with Aurora B inhibition. Yang et al (45) demonstrated the phenotypes consistent with Aurora B inhibition are dominant over those consistent with
Aurora A when both kinases are inhibited. Taken together, these data demonstrates a selectivity window of alisertib for Aurora A kinase over Aurora B kinase in enzyme and cell-based assays.

We used novel *in vivo* assays assessing quantitative spindle bipolarity and chromosome alignment to monitor Aurora A activity *in vivo*. These assays demonstrated that at the MTD in mice, alisertib treatment reduced spindle bipolarity and increased chromosome misalignment. Our findings indicate that by 8 hrs, spindle bipolarity but not chromosomal alignment had partially recovered in the 30 mg/kg dose group, and that the majority of spindles in this dose group were bipolar, with misaligned chromosomes. These results are consistent with the findings reported by us as well as others in cell culture (7, 33, 41, 46) and suggests that Aurora A inhibition leads to transient mitotic arrest followed by inappropriate passage through anaphase in the presence of misaligned chromosomes.

The transient nature and slow onset of the mitotic delays that occur with Aurora A inhibition led us to investigate these alternative mechanism-based pharmacodynamic biomarkers with a more rapid onset than the mitotic index. It is interesting to note that there is a substantial difference in time between peak mitotic index (8 to 12 hrs; Fig. 2A) compared to the peak changes in the chromosome alignment and spindle bipolarity assays (1 hr; Fig. 2C and D). One potential explanation for this is that the mitotic index assay, which measures the
fraction of mitotic cells in the entire population, requires several hours to accumulate mitotic cells, whereas the spindle bipolarity/chromosomal alignment assays focus on cells that are currently in mitosis, where the loss of mitotic spindle integrity upon Aurora A inhibition is rapid. An alternative explanation for the difference in kinetics between the mitotic index and the spindle bipolarity/chromosome alignment assays is the previously described role for Aurora A in mitotic commitment. Such a reduction in the rate of mitotic entry would be consistent with the delayed increase in the mitotic index observed with Aurora A inhibition.

Aurora A inhibition results in a delayed mitosis followed by an abnormal cellular division. One commonly reported outcome of Aurora A inhibition is a postmitotic p53-dependent G1 arrest (47), that in some cases has been shown to lead to apoptosis. Cellular senescence has also been demonstrated to be a long-term effect of Aurora A inhibition in vitro and in vivo (8).

Using markers of S-phase, BrdU, which gets incorporated into DNA, and FLT, which is phosphorylated and trapped in cells by the S-phase active thymidine kinase 1, we detected an inhibition of proliferation in vitro and in vivo. In both cases alisertib reduced the number of cells in S-phase. This could be due to transient mitotic delay, consistent with a pharmacodynamic effect of Aurora A inhibition, or due to cells undergoing apoptosis or cellular senescence. Inhibition of proliferation by Aurora A inhibition has been shown to be mediated by two
known terminal outcomes including apoptosis and cellular senescence (8, 32).

For the in vivo study, there was an initial decrease in FLT uptake followed by a gradual decline to day 21. We have previously shown with MLN8054, another Aurora A inhibitor similar to alisertib, that cells continue to divide for several divisions over the first few days following AurA inhibition (7), and undergo apoptosis as well as cell-cycle arrest during this period. This suggests that the initial decrease in FLT may not be due to senescence but rather apoptosis or the initial activation of the p53-dependent G1 arrest. However, at later timepoints the decrease in FLT may be due to cellular senescence, as we have previously demonstrated; senescence, as detected by beta galactosidase staining, does not set in until day 15 and is maximal at day 21 (8).

Taken together, our data demonstrate that alisertib is a selective and potent inhibitor of Aurora A kinase. In addition, we have developed novel pharmacodynamic assays to assess Aurora A target inhibition in the clinic. To this end, the spindle bipolarity and chromosome alignment assays are currently being deployed on patient skin and tumor biopsies in phase I clinical trials. This data also suggests that FLT PET may be a valid non-invasive modality to understand multiple mechanisms of Aurora A inhibition including cellular senescence.
Acknowledgements

The authors would like to acknowledge Catherine Crookes of FireKite for editing assistance in the development of this manuscript, which was funded by Millennium Pharmaceuticals, Inc.

References


**Table legends**

**Table 1.** IC\textsubscript{50} values of alisertib A) against recombinant Aurora A and Aurora B as determined by a radioactive Flashplate™ assay, against Aurora A and Aurora B activity in HeLa cells, and B) inhibition of proliferation by alisertib in tumor cell lines, as assessed by the BrdU cell proliferation assay.

**Table 2.** Alisertib antitumor activity across nine tumor models of different histologies grown subcutaneously or disseminated. Mice for all models were dosed orally with alisertib for approximately three weeks and percent tumor growth inhibition was calculated on the last day of treatment. ND, not done

**Fig. Legends**

**Fig. 1.** *In vitro* cell-based phenotypes consistent with Aurora A and Aurora B inhibition at low and high concentrations, respectively.

A, Flow cytometric DNA profiles of HCT-116 cells treated with DMSO or alisertib for 24 or 48 hrs. Peaks 2N, 4N, and 8N reflect relative DNA content and represent diploid, tetraploid, and multinucleated cells, respectively.

B, Representative immunofluorescent images of HCT-116 cells treated with DMSO or alisertib (0.050, 0.250, and 1.000 \( \mu \)M) for 24 hrs. Overlapped images were obtained from cells stained with anti-\( \alpha \)-tubulin mouse antibody (tubulin, green) and Hoechst (DNA, blue). Arrows indicate mitotic spindles and asterisks indicate multinucleated cells.
Fig. 2. Pharmacodynamic activity of alisertib in the HCT-116 xenograft model as determined by increased mitotic index, misaligned chromosomes, and reduced bipolar mitotic spindles. HCT-116 tumors were treated orally with a single dose of 3, 10, and 30 mg/kg alisertib and were removed at the time points shown.

A, Change in mitotic index, as indicated by the mitotic marker pHisH3, following a single dose of alisertib at increasing concentrations. Tumors were stained for the mitotic marker pHisH3 using immunofluorescence detection, and quantified at the indicated time-points following a single dose.

B, Representative examples of mitotic cells taken over the first 4 hrs post-alisertib. Mitotic spindles (green) were stained for alpha-tubulin, while DNA (blue) was stained with DAPI. Representative spindles are shown from each time point, showing a broad dose- and time-dependent decrease in the degree of chromosome alignment and spindle bipolarity during mitosis, consistent with the described mechanism of Aurora A.

C, Percentage of aligned mitotic spindles at each alisertib dose over 8 hrs, as quantified by blinded, randomized visual scoring at each of the indicated time-points.

D, Percentage of bipolar mitotic spindles at each alisertib dose over 8 hrs, as similarly quantified by blinded, randomized visual scoring. Both measures show a relatively rapid dose-dependent decrease that appears to peak around 1 hr post-dosing (at the highest dose).
**Fig. 3.** Broad antitumor activity of alisertib in a diverse set of human tumor xenograft models.

A, Nude mice bearing subcutaneous HCT-116 tumors were dosed with alisertib orally at 3, 10, and 30 mg/kg QD for 21 consecutive days. Mean tumor volumes (mm$^3$) ± SEM ($n = 10$/group) are shown from the beginning of treatment.

B, OCI-LY19 tumors inoculated intravenously were treated with alisertib at 20 mg/kg BID, 30 mg/kg QD and with rituximab at 10 mg/kg once per week. Tumor burden was measured using bioluminescent imaging and expressed as whole body photon flux ± SEM ($n = 10$/group). BID, twice-daily; QD, once-daily

**Fig. 4.** Alisertib reduces FLT uptake in HCT-116 tumors. HCT-116 tumors ($n = 8$/group) were treated with alisertib at 20 mg/kg BID for 21 consecutive days. Mice bearing the tumors were injected with F$^{18}$-FLT on days 0 (pretreatment), 7, 14, and 21 and imaged using positron emission tomography (PET).

A, Normalized tumor volume of vehicle- and alisertib-treated mice using PET imaging.

B, FLT uptake in vehicle control tumor and alisertib treated tumors using normalized SUVvol as described in the methods.
Table 1

A) Selectivity assay: Radioactive Flashplate™

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>MLN8237 IC₅₀ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aurora A</strong></td>
<td></td>
</tr>
<tr>
<td>Recombinant Aurora A</td>
<td>1.2</td>
</tr>
<tr>
<td>HeLa</td>
<td>6.7</td>
</tr>
<tr>
<td><strong>Aurora B</strong></td>
<td></td>
</tr>
<tr>
<td>Recombinant Aurora B</td>
<td>396.5</td>
</tr>
<tr>
<td>HeLa</td>
<td>1534</td>
</tr>
</tbody>
</table>

B) BrdU cell proliferation assay

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>MLN8237 IC₅₀ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colon</strong></td>
<td></td>
</tr>
<tr>
<td>HCT-116</td>
<td>32 ± 10 (8)ᵃ</td>
</tr>
<tr>
<td>SW480</td>
<td>431 ± 159 (8)</td>
</tr>
<tr>
<td>DLD-1</td>
<td>469 (1)</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td></td>
</tr>
<tr>
<td>H460</td>
<td>16 (1)</td>
</tr>
<tr>
<td><strong>Breast</strong></td>
<td></td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>190 (1)</td>
</tr>
<tr>
<td><strong>Prostate</strong></td>
<td></td>
</tr>
<tr>
<td>PC3</td>
<td>54 (1)</td>
</tr>
<tr>
<td><strong>Ovarian</strong></td>
<td></td>
</tr>
<tr>
<td>SKOV3</td>
<td>111 (1)</td>
</tr>
<tr>
<td><strong>Pancreatic</strong></td>
<td></td>
</tr>
<tr>
<td>HPAC</td>
<td>130 (1)</td>
</tr>
<tr>
<td><strong>Lymphoma (DLBCLs)</strong></td>
<td></td>
</tr>
<tr>
<td>OCI-LY-3</td>
<td>43 (1)</td>
</tr>
<tr>
<td>OCI-LY-7</td>
<td>86 (1)</td>
</tr>
<tr>
<td>OCI-LY-10</td>
<td>16 (1)</td>
</tr>
<tr>
<td>OCI-LY-19</td>
<td>15 (1)</td>
</tr>
<tr>
<td>WSU</td>
<td>50 (1)</td>
</tr>
</tbody>
</table>

IC₅₀, half maximal inhibitory concentration

ᵃNumbers represent average IC₅₀ ± standard deviation derived from the BrdU cell proliferation ELISA assay. Numbers in parentheses represent the number of experiments completed.
<table>
<thead>
<tr>
<th>Tumor growth inhibition (%)</th>
<th>QD dosing (mg/kg)</th>
<th>BID dosing (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>Colon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCT-116</td>
<td>48</td>
<td>81</td>
</tr>
<tr>
<td>DLD-1</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calu-6</td>
<td>ND</td>
<td>-11</td>
</tr>
<tr>
<td>H460</td>
<td>21</td>
<td>43</td>
</tr>
<tr>
<td>Prostate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CWR22</td>
<td>ND</td>
<td>50</td>
</tr>
<tr>
<td>Breast</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCI-Ly7</td>
<td>ND</td>
<td>90</td>
</tr>
<tr>
<td>OCI-Ly19</td>
<td>89</td>
<td>104</td>
</tr>
<tr>
<td>WSU</td>
<td>51</td>
<td>92</td>
</tr>
</tbody>
</table>

Research.
**Figure 2**

**A**

Graph showing the percentage of mitotic (pHisH3) cells over time for different doses of MLN8237:
- 3 mg/kg
- 10 mg/kg
- 30 mg/kg

**B**

Images showing the effect of different doses of MLN8237 on the cell morphology over time.

**C**

Graph showing the percentage of aligned cells over time post dose for different doses of MLN8237:
- 3 mg/kg
- 10 mg/kg
- 30 mg/kg

**D**

Graph showing the percentage of bipolar cells over time post dose for different doses of MLN8237:
- 3 mg/kg
- 10 mg/kg
- 30 mg/kg

*Note: The graph images are not reproducible here, but they illustrate the effects of different doses on the cell cycle and morphology.*
Figure 3

A

Vehicle
3 mg/kg QD
10 mg/kg QD
30 mg/kg QD

B

Vehicle
MLN8237 30mg/kg QD
MLN8237 20mg/kg BID
Rituximab 10mg/kg
Figure 4

A

B
Characterization of Alisertib (MLN8237), An Investigational Small Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

Mark G. Manfredi, Jeffrey A. Ecsedy, Arijit Chakravarty, et al.

Clin Cancer Res Published OnlineFirst October 20, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-1536

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/10/20/1078-0432.CCR-11-1536.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.